CO6361936A2 - Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa - Google Patents
Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasaInfo
- Publication number
- CO6361936A2 CO6361936A2 CO11043111A CO11043111A CO6361936A2 CO 6361936 A2 CO6361936 A2 CO 6361936A2 CO 11043111 A CO11043111 A CO 11043111A CO 11043111 A CO11043111 A CO 11043111A CO 6361936 A2 CO6361936 A2 CO 6361936A2
- Authority
- CO
- Colombia
- Prior art keywords
- useful
- imidazopiridazinacarbonitrilos
- quinase
- inhibitors
- quinase inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000005233 imidazopyridazines Chemical class 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10404508P | 2008-10-09 | 2008-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6361936A2 true CO6361936A2 (es) | 2012-01-20 |
Family
ID=41718919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11043111A CO6361936A2 (es) | 2008-10-09 | 2011-04-07 | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8252795B2 (OSRAM) |
| EP (1) | EP2350081B1 (OSRAM) |
| JP (1) | JP5560278B2 (OSRAM) |
| KR (1) | KR20110075010A (OSRAM) |
| CN (1) | CN102245609B (OSRAM) |
| AR (1) | AR073818A1 (OSRAM) |
| AU (1) | AU2009302360B2 (OSRAM) |
| BR (1) | BRPI0920135A2 (OSRAM) |
| CA (1) | CA2739782A1 (OSRAM) |
| CL (1) | CL2011000777A1 (OSRAM) |
| CO (1) | CO6361936A2 (OSRAM) |
| CY (1) | CY1114539T1 (OSRAM) |
| DK (1) | DK2350081T3 (OSRAM) |
| EA (1) | EA018163B1 (OSRAM) |
| ES (1) | ES2426951T3 (OSRAM) |
| HR (1) | HRP20130787T1 (OSRAM) |
| IL (1) | IL211693A (OSRAM) |
| MX (1) | MX2011003304A (OSRAM) |
| NZ (1) | NZ591712A (OSRAM) |
| PE (1) | PE20110411A1 (OSRAM) |
| PL (1) | PL2350081T3 (OSRAM) |
| PT (1) | PT2350081E (OSRAM) |
| SI (1) | SI2350081T1 (OSRAM) |
| SM (1) | SMT201300109B (OSRAM) |
| TW (1) | TWI491610B (OSRAM) |
| WO (1) | WO2010042699A1 (OSRAM) |
| ZA (1) | ZA201102423B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9587033B2 (en) | 2010-11-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting TNK-1 |
| CA2821837A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| WO2012080229A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| WO2012080234A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2701507A1 (en) * | 2011-04-26 | 2014-03-05 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| EP2827869A4 (en) | 2012-03-23 | 2015-09-23 | Dennis Brown | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGUE THEREOF, WITH MEISOINDIGO |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| AP2015008898A0 (en) | 2013-06-11 | 2015-12-31 | Bayer Pharma AG | Prodrug derivatives of substituted triazolopyridines |
| CN105764502A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群及其类似物及衍生物的治疗益处的组合方法 |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6843135B2 (ja) | 2015-11-18 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| US10227344B2 (en) | 2016-06-24 | 2019-03-12 | Polaris Pharmaceuticals, Inc. | CK2 inhibitors, compositions and methods thereof |
| MA45940B1 (fr) * | 2016-08-10 | 2024-12-31 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| JP7012082B2 (ja) | 2016-11-17 | 2022-01-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 |
| JP7129420B6 (ja) | 2017-03-30 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｐｋ１阻害剤としてのイソキノリン |
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN109988150B (zh) | 2017-12-29 | 2022-04-12 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| BR112020013313B1 (pt) | 2017-12-29 | 2023-10-31 | Jiangsu Flag Chemical Industry Co., Ltd | Composto de pirazolamida de fórmula geral i, composto de fórmula ii, método para preparar um composto de fórmula geral i, uso do composto de fórmula geral i, composição inseticida e método para controlar pragas |
| WO2019128871A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| CN111867581B (zh) * | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
| PE20211275A1 (es) | 2018-07-09 | 2021-07-19 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos antihelminticos |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| ES2987809T3 (es) | 2019-03-05 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa |
| KR20220002890A (ko) | 2019-03-19 | 2022-01-07 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물 |
| CN117986251A (zh) | 2019-04-24 | 2024-05-07 | 拜耳股份有限公司 | 4H-吡咯并[3,2-c]吡啶-4-酮化合物 |
| CA3137611A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3959212A1 (en) | 2019-04-24 | 2022-03-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| WO2021198020A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| MX2022015038A (es) | 2020-05-29 | 2023-01-04 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos como anthelminticos. |
| MX2023009094A (es) * | 2021-02-03 | 2023-08-09 | Sanofi Sa | Derivados de imidazo[4,5-d]piridazina, su preparacion y su aplicacion terapeutica. |
| PE20250675A1 (es) | 2021-11-01 | 2025-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Compuestos de pirrolopiridazina como antihelminticos |
| IL314397A (en) * | 2022-01-25 | 2024-09-01 | Kinnate Biopharma Inc | CDK4/6 kinase inhibitors |
| WO2024039767A1 (en) * | 2022-08-18 | 2024-02-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |
| CN115947756B (zh) * | 2022-12-13 | 2025-08-01 | 西湖大学 | 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ333302A (en) | 1996-08-28 | 2000-08-25 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor |
| CN1173975C (zh) | 2000-04-27 | 2004-11-03 | 山之内制药株式会社 | 咪唑并吡啶衍生物 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| JP2006519753A (ja) | 2002-11-15 | 2006-08-31 | イデニクス（ケイマン）リミテツド | ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異 |
| CA2551867C (en) * | 2003-12-31 | 2010-08-17 | Schering-Plough Ltd. | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
| EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CN101048158A (zh) * | 2004-08-13 | 2007-10-03 | 健泰科生物技术公司 | 利用atp的酶的噻唑－类抑制剂 |
| WO2006070943A1 (ja) * | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| AR056191A1 (es) | 2005-08-23 | 2007-09-26 | Idenix Phatmaceuticals Inc | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8044049B2 (en) * | 2006-08-04 | 2011-10-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP1911451A1 (en) * | 2006-10-10 | 2008-04-16 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Protein-kinase CK2 inhibitors and their therapeutic applications |
| JP2010508314A (ja) * | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 脂質キナーゼ阻害剤としてのイミダゾピリダジン |
| CA2684932A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
-
2009
- 2009-10-01 TW TW098133429A patent/TWI491610B/zh not_active IP Right Cessation
- 2009-10-08 ES ES09740573T patent/ES2426951T3/es active Active
- 2009-10-08 EP EP09740573.2A patent/EP2350081B1/en not_active Not-in-force
- 2009-10-08 MX MX2011003304A patent/MX2011003304A/es active IP Right Grant
- 2009-10-08 WO PCT/US2009/059968 patent/WO2010042699A1/en not_active Ceased
- 2009-10-08 PT PT97405732T patent/PT2350081E/pt unknown
- 2009-10-08 SI SI200930729T patent/SI2350081T1/sl unknown
- 2009-10-08 BR BRPI0920135A patent/BRPI0920135A2/pt not_active IP Right Cessation
- 2009-10-08 AU AU2009302360A patent/AU2009302360B2/en not_active Ceased
- 2009-10-08 CN CN200980149133.2A patent/CN102245609B/zh not_active Expired - Fee Related
- 2009-10-08 US US12/575,589 patent/US8252795B2/en active Active
- 2009-10-08 CA CA2739782A patent/CA2739782A1/en not_active Abandoned
- 2009-10-08 KR KR1020117010394A patent/KR20110075010A/ko not_active Ceased
- 2009-10-08 JP JP2011531168A patent/JP5560278B2/ja not_active Expired - Fee Related
- 2009-10-08 DK DK09740573.2T patent/DK2350081T3/da active
- 2009-10-08 HR HRP20130787AT patent/HRP20130787T1/hr unknown
- 2009-10-08 PE PE2011000814A patent/PE20110411A1/es not_active Application Discontinuation
- 2009-10-08 NZ NZ591712A patent/NZ591712A/xx not_active IP Right Cessation
- 2009-10-08 PL PL09740573T patent/PL2350081T3/pl unknown
- 2009-10-08 EA EA201100580A patent/EA018163B1/ru not_active IP Right Cessation
- 2009-10-09 AR ARP090103910A patent/AR073818A1/es unknown
-
2011
- 2011-03-10 IL IL211693A patent/IL211693A/en not_active IP Right Cessation
- 2011-03-31 ZA ZA2011/02423A patent/ZA201102423B/en unknown
- 2011-04-07 CO CO11043111A patent/CO6361936A2/es active IP Right Grant
- 2011-04-07 CL CL2011000777A patent/CL2011000777A1/es unknown
-
2012
- 2012-07-19 US US13/552,795 patent/US20120283241A1/en not_active Abandoned
-
2013
- 2013-09-30 CY CY20131100844T patent/CY1114539T1/el unknown
- 2013-10-02 SM SM201300109T patent/SMT201300109B/xx unknown
-
2014
- 2014-02-27 US US14/191,861 patent/US9371328B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| UY39630A (es) | Inhibidores de bromodominios | |
| UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
| MX2019010602A (es) | Inhibidores de cdk. | |
| CO7180199A2 (es) | Imidazotriazincarbonitrilos útiles como inhibidores de cinasa | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| CR20150474A (es) | Inhibidores de bromodominios tetracíclicos | |
| CO6390057A2 (es) | Indazoles oxazol sustituidos como inhibidores de pi3-quinasa | |
| CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| UY30500A1 (es) | Compuestos de azabencimidazolilo | |
| CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
| CR20160035A (es) | Inhibidores de bromodominios | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| CR20120510A (es) | Derivados de piperidin-4-il azetidina como inhibidores de jak1 | |
| ECSP088121A (es) | Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CR11803A (es) | Pirrolopiridinas como inhibidores de cinasa | |
| MD4556B1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| MX2012004311A (es) | Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes. | |
| CR20110269A (es) | Lactamas como inhibidores de beta secretasa | |
| CU20110220A7 (es) | Espiro-epóxidos como productos intermedios | |
| CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
| ECSP10010597A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| GT200600366A (es) | Compuestos de imidazol sustituido como inhibidores de ksp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |